Literature DB >> 18953066

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.

Y Akiyama, K Fujita, F Nagashima, W Yamamoto, H Endo, Y Sunakawa, K Yamashita, H Ishida, K Mizuno, K Araki, W Ichikawa, T Miya, M Narabayashi, K Kawara, M Sugiyama, T Hirose, Y Ando, Y Sasaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18953066      PMCID： PMC2733123          DOI： 10.1093/annonc/mdn645

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Authors:  Y Ando; H Saka; M Ando; T Sawa; K Muro; H Ueoka; A Yokoyama; S Saitoh; K Shimokata; Y Hasegawa
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

2.  Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

Authors:  Kazuhiro Araki; Ken-ichi Fujita; Yuichi Ando; Fumio Nagashima; Wataru Yamamoto; Hisashi Endo; Toshimichi Miya; Keiji Kodama; Masaru Narabayashi; Yasutsuna Sasaki
Journal:  Cancer Sci       Date:  2006-09-12       Impact factor: 6.716

3.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Authors:  Federico Innocenti; Samir D Undevia; Lalitha Iyer; Pei Xian Chen; Soma Das; Masha Kocherginsky; Theodore Karrison; Linda Janisch; Jacqueline Ramírez; Charles M Rudin; Everett E Vokes; Mark J Ratain
Journal:  J Clin Oncol       Date:  2004-03-08       Impact factor: 44.544

4.  UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Authors:  Janelle M Hoskins; Richard M Goldberg; Pingping Qu; Joseph G Ibrahim; Howard L McLeod
Journal:  J Natl Cancer Inst       Date:  2007-08-28       Impact factor: 13.506

5.  Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

Authors:  Hironobu Minami; Kimie Sai; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Kazuhiro Suzuki; Nahoko Kaniwa; Jun-ichi Sawada; Tetsuya Hamaguchi; Noboru Yamamoto; Kuniaki Shirao; Yasuhide Yamada; Hironobu Ohmatsu; Kaoru Kubota; Teruhiko Yoshida; Atsushi Ohtsu; Nagahiro Saijo
Journal:  Pharmacogenet Genomics       Date:  2007-07       Impact factor: 2.089
  5 in total
  13 in total

Review 1.  Recent progress and clinical importance on pharmacogenetics in cancer therapy.

Authors:  Thomas I Peng Soh; Wei Peng Yong; Federico Innocenti
Journal:  Clin Chem Lab Med       Date:  2011-09-28       Impact factor: 3.694

2.  Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.

Authors:  Shouji Shimoyama
Journal:  World J Gastrointest Surg       Date:  2010-01-27

3.  Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.

Authors:  Keisuke Kazama; Manabu Shiozawa; Masakatsu Numata; Nobuhiro Sugano; Sumito Sato; Mamoru Uchiyama; Maho Sato; Toru Aoyama; Hiroshi Tamagawa; Takashi Oshima; Norio Yukawa; Yasushi Rino
Journal:  Int J Colorectal Dis       Date:  2021-11-12       Impact factor: 2.571

4.  Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy.

Authors:  Taishi Harada; Haruhiro Saito; Fumi Karino; Tetsuya Isaka; Shuji Murakami; Tetsuro Kondo; Fumihiro Oshita; Yohei Miyagi; Kouzo Yamada
Journal:  Mol Clin Oncol       Date:  2014-06-06

Review 5.  Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

Authors:  Ken-ichi Fujita; Yutaro Kubota; Hiroo Ishida; Yasutsuna Sasaki
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

6.  UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.

Authors:  Shoichi Hazama; Hideyuki Mishima; Ryouichi Tsunedomi; Yusuke Okuyama; Takeshi Kato; Ken-ichi Takahashi; Hiroshi Nozawa; Hideaki Ando; Michiya Kobayashi; Hiroyoshi Takemoto; Naoki Nagata; Shinsuke Kanekiyo; Yuka Inoue; Yoshihiko Hamamoto; Yusuke Fujita; Yuji Hinoda; Naoko Okayama; Koji Oba; Jun-ichi Sakamoto; Masaaki Oka
Journal:  Cancer Sci       Date:  2013-10-27       Impact factor: 6.716

Review 7.  Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.

Authors:  Wei-qin Jiang; Fang-fang Fu; Yang-xia Li; Wei-bin Wang; Hao-hao Wang; Hai-ping Jiang; Li-song Teng
Journal:  J Zhejiang Univ Sci B       Date:  2012-09       Impact factor: 3.066

8.  Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project.

Authors:  Keiko Hikino; Takeshi Ozeki; Masaru Koido; Chikashi Terao; Yoichiro Kamatani; Yoshinori Murakami; Michiaki Kubo; Taisei Mushiroda
Journal:  J Hum Genet       Date:  2019-10-04       Impact factor: 3.172

9.  Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.

Authors:  Ayako Tsuboya; Yutaro Kubota; Hiroo Ishida; Ryotaro Ohkuma; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Takuya Tsunoda; Yasutsuna Sasaki; Natsumi Matsumoto; Yusuke Kondo; Yukana Tomoda; Hiroyuki Kusuhara; Ken-Ichi Fujita
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-11       Impact factor: 3.333

10.  Pharmacogenetic study of deferasirox, an iron chelating agent.

Authors:  Ji Won Lee; Hyoung Jin Kang; Ji-Yeob Choi; Nam Hee Kim; Mi Kyung Jang; Chang-Woo Yeo; Sang Seop Lee; Hyery Kim; June Dong Park; Kyung Duk Park; Hee Young Shin; Jae-Gook Shin; Hyo Seop Ahn
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.